Multiple Programs from Merrimack Pharmaceuticals' Pipeline to be Presented at the 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Poster presentations on MM-398, MM-121, MM-111, MM-302, MM-151 and MM-141

First public presentation on MM-141, a novel bispecific antibody designed to simultaneously target and inhibit IGF-1R and ErbB3 (HER3)

CAMBRIDGE, Mass., Nov. 11, 2011 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. announced today that they will present seven posters on six novel pipeline programs at the 2011 American Association for Cancer Research (AACR)/National Cancer Institute (NCI)/European Organization for Research and Treatment of Cancer (EORTC) International Conference on Molecular Targets and Cancer Therapeutics taking place November 12-16, 2011, in San Francisco, California.

(Logo: http://photos.prnewswire.com/prnh/20100913/NE63515LOGO )

MM-398

 

MM-398 is a novel, stable nanotherapeutic encapsulation of irinotecan. The U.S. Food and Drug Administration (FDA) has granted MM-398 orphan drug status for use in the treatment of pancreatic cancer. PharmaEngine, Inc. has rights to develop and commercialize MM-398 in Taiwan under the designation PEP02.


 

 

Title:

Poster Session:

Number:

Date/Time:

Location:

West Hall, Level One, Moscone Center West Tuesday, Nov 15, 2011, 12:30 PM – 2:30 PM C207 Topoisomerase Inhibitors Identifying differential mechanisms of action for MM-398/PEP02, a nove l nanotherapeutic encapsulation of irinotecan
 


 

 
   


 

MM-121

MM-121 is a monoclonal antibody designed to block signaling through the ErbB3 (HER3) receptor. MM-121, in partnership with Sanofi, is in clinical development in patients with breast, lung and ovarian cancer.


 

 

Title:

Poster Session:

Number:

Date/Time:

Location:

West Hall, Level One, Moscone Center West Tuesday, Nov 15, 2011, 12:30 PM – 2:30 PM C27 Clinical Trials 3 Targeting ErbB3 (HER3) and EGFR in Lung Cancer Patients: A Phase I Trial of MM-121 in Combination with Erlotinib in Patients with Non-Small Cell Lung Cancer (NSCLC)
 


 

 
   


 

MM-111

 

MM-111 is a novel bispecific antibody against ErbB3 (HER3), using an ErbB2 (HER2) targeting arm to enhance avidity and inhibition.


 

 

Title:

Poster Session:

Number:

Date/Time:

Location:

West Hall, Level One, Moscone Convention Center West Tuesday, Nov 15, 12:30 PM – 2:30 PM C118 Pharmacokinetics and Pharmacodynamics 3 Optimization of MM-111 and lapatinib dosing regimens using mathematical modeling and quantitative biology
 


 

 
   


 

MM-302

 

MM-302 is a nanotherapeutic encapsulation of doxorubicin designed to target ErbB2 (HER2) overexpressing cancer cells, while limiting uptake into non-target cells.


 

 

Title:

Poster Session:

Number:

Date/Time:

Location:

West Hall, Level One, Moscone Center West Tuesday, Nov 15, 2011, 12:30 PM – 2:30 PM C90 Novel Assay Technology HER2-targeted liposomal doxorubicin, MM-302, has a favorable cardiosafety profile in preclinical models
 


 

 
   


 

MM-151

 

MM-151 is a mixture of three fully human monoclonal antibodies directed against distinct non-overlapping epitopes in EGFR.


 

 

Title:

Poster Session:

Number:

Date/Time:

Location:

West Hall, Level One, Moscone Center West Sunday, Nov 13, 2011, 12:30 PM – 2:30 PM A210 Therapeutic Agents: Biological 1 Elucidating mechanisms of action of MM-151, a mixture of three human antibody antagonists targeting EGFR
 


 

 
   


 


 

 

Title:

Poster Session:

Number:

Date/Time:

Location:

West Hall, Level One, Moscone Center West Sunday, Nov 13, 2011, 12:30 PM – 2:30 PM A144 EGFR / Her2 Therapeutically targeting high-affinity ligand activation of EGFR with MM-151, an oligoclonal therapeutic
 


 

 
   


 

MM-141

 

MM-141 is a comprehensive IGF-1R signaling inhibitor that is designed to address the redundancies that occur in tumors where both IGF-1R and ErbB3 (HER3) are activated, an approach intended to improve patient response by blocking survival signaling promoted by two separate pathways.


 

 

Title:

Poster Session:

Number:

Date/Time:

Location:

West Hall, Level One, Moscone Convention Center West Monday, Nov 14, 2011, 12:30 PM – 2:30 PM B205 Therapeutic Agents: Biological 2 Therapeutically targeting redundant, growth factor-induced pro-survival signaling with MM-141, a novel bispecific antibody targeting IGF-1R and ErbB3 (HER3)
 


 

 
   


 

About Merrimack

Merrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer. Merrimack applies Network Biology, its proprietary systems biology-based approach to biomedical research, throughout the research and development process. Merrimack currently has four targeted therapeutic oncology candidates in clinical development and a fifth expected to enter clinical development by early 2012.

Contact: Kathleen Petrozzelli Gallagher, Corporate Communications, Merrimack, 617-441-1043, kgallagher@merrimackpharma.com

Betsy Stevenson, RaymondStevenson Healthcare Communications, 860-984-1424, betsy@raymondstevenson.com

SOURCE Merrimack Pharmaceuticals, Inc.

Web Site: http://www.merrimackpharma.com

Posted: November 2011

View comments

Hide
(web3)